| What it does | AI-powered stock screener and backtesting platform for US equity traders
| Stock screener scoring 1,500+ US stocks using five classic investment models
|
|---|
| Stage | Not given
| Startup
|
|---|
| Founded | Not given
| 2024
|
|---|
| Based in | Not given
| Not given
|
|---|
| Pricing model | Freemium
| Not given
|
|---|
| Pricing | Not given
| Free: $0/forever includes all 1,500+ composite scores, 4-axis score breakdown, results of all 5 models' tests, recent score history, screener with 5 basic filters, peer comparison and watchlist for 3 stocks. Premium: $3.33/mo when billed annually ($40/yr) or $5/mo monthly, adds figures behind every
|
|---|
| Key features | - Stock screener with technical and fundamental filters
- Screener backtesting with historical win rates and drawdowns
- Watchlists for tracking stocks
- Real-time market news with sentiment analysis
- Sector heatmap showing rotation and performance
- Economic and corporate event calendar
- Seasonality patterns with historical frequency analysis
- Chart pattern recognition
- AI-powered Dr. Market assistant with real data feeds
| - 1,500+ stocks scored across S&P 500, MidCap 400, SmallCap 600 and ADRs
- Four-axis composite score: Quality, Value, Momentum, Timing
- Daily data updates from SEC EDGAR and Alpaca Markets
- Sector-specific calibration across 7 sector profiles
- Stock screener with basic and advanced filters
- Fair value estimates per stock
- Point-in-time backtest published in full
|
|---|
| What makes it different | - AI analysis based only on real market data feeds, never generating numbers from memory
- All-in-one trading ecosystem consolidating screening, news, charts, and analysis
- Backtesting with complete drawdown visibility alongside win rates
- Direct founder support without ticket maze
- Analysis tool for validating theses, not investment advice service
| - Transparent methodology: every score computed as its source defines it with published thresholds
- No personalized recommendations: algorithm-generated scores presented as research tools, not buy/sell signals
- Backtest results published in full including failures
- Free access to all core scores and analysis tools without credit card or trial limits
|
| Community votes | 0 | 0 |
| DR (Domain Rating by Ahrefs) | 5 ● no change since last check | Not checked yet ● no change since last check |
| Trust Flow (Majestic) | 3 | 0 |
| Citation Flow (Majestic) | 29 | 13 |
| Referring domains (Majestic) | 68 | 2 |